Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ideagen Plc LSE:IDEA London Ordinary Share GB00B0CM0C50 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 217.50 108,049 08:00:27
Bid Price Offer Price High Price Low Price Open Price
215.00 220.00 217.50 217.00 217.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 56.57 -0.13 -0.09 493
Last Trade Time Trade Type Trade Size Trade Price Currency
17:55:05 O 4,849 220.022 GBX

Ideagen (IDEA) Latest News

More Ideagen News
Ideagen Investors    Ideagen Takeover Rumours

Ideagen (IDEA) Discussions and Chat

Ideagen (IDEA) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ideagen trades in real-time

Ideagen (IDEA) Top Chat Posts

DateSubject
28/11/2020
08:20
Ideagen Daily Update: Ideagen Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker IDEA. The last closing price for Ideagen was 217.50p.
Ideagen Plc has a 4 week average price of 211.50p and a 12 week average price of 190p.
The 1 year high share price is 237p while the 1 year low share price is currently 93.44p.
There are currently 226,843,008 shares in issue and the average daily traded volume is 163,113 shares. The market capitalisation of Ideagen Plc is £493,383,542.40.
27/11/2020
14:35
sharesoc: We are hosting a webinar with Ideagen on the 2nd December. May be worth watching if you are a current shareholder or potential investor. Ben Dorks (CEO) and Emma Hayes (CFO) will be presenting: hTTps://www.sharesoc.org/events/sharesoc-webinar-with-ideagen-idea-2-december-2020/
03/11/2020
12:07
halfpenny: IDEA HEADING MUCH higher. Great company with very Sticky Customers and a High Demand fir their Products and Services. Great Team...250 plus plus more to cone as news flow...
13/7/2020
12:02
redalert: Davidosh, it seems IDEA did not present at Mello after all - is there any reason for that? thank you. RA
05/7/2020
14:17
maddox: thanks sema, very positive update from Ben, great to hear that the sales are holding up. Looking forward to seeing them at Mellow Virtual - IDEA are excellent in regards to shareholder engagement.
03/7/2020
13:53
semaj2000: IDEA on Vox Markets Podcast - https://bit.ly/2ZyEvLp
22/5/2020
08:54
halfpenny: A fantastic move by IDEA. This gives them a World stage to launch their great products and services. Sales will rocket and so will the share price as its great value and steady...WELL DONE!!!
11/10/2019
06:06
multibagger: 11/10/2019 7:00am RNS Non-Regulatory Ideagen PLC ("Ideagen" "the Company" or "the Group") Acquisition of Optima Diagnostics Limited Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to announce the acquisition of the entire issued share capital of Optima Diagnostics Ltd ("Optima") for a cash consideration of GBP1.8m (the "Acquisition") paid on completion from the Company's existing resources. Highlights -- Optima is a Software as a Service ("SaaS") company that has developed OSHENS, a SaaS based Health and Safety compliance solution -- Optima has approximately 80 customers across highly regulated markets including Aerospace and Defence, Aviation and Energy - customers include Airbus, Sellafield, BAE Systems and Edinburgh Airport -- This Acquisition supports the Group's strategy as a consolidator within the Global Quality, Health, Safety and Environmental ("QHSE") software market -- On a current run rate Optima is generating approximately GBP1m in revenues (of which GBP0.9m is recurring) generating EBITDA of GBP0.1m -- The Acquisition is expected to contribute GBP0.3m additional annual EBITDA to the Group following the realisation of identified synergies David Hornsby, Executive Chairman of Ideagen, commented; "Optima is a valuable addition to Ideagen and is in line with our strategy of acquiring businesses that have strong IP and recurring revenues. EHSQ is a valuable yet fragmented market and the acquisition will further enhance our market position as we aim to further consolidate this sector.
19/8/2019
08:02
rivaldo: Nice mention here re Montanaro's buying and the increase in their holding: Https://citywire.co.uk/funds-insider/news/five-shares-the-pros-are-buying-and-selling/a1260329 "Ideagen (IDEA) Who’s trading? Citywire AA-rated Charles Montanaro The trade: The founder of the eponymous small cap firm ramped up his stake in compliance and risk management software firm Ideagen from 2% of shares to 3.1%. How have the shares performed? Ideagen stock rocketed 264% over the three years to September 2018 to a record high of 172p but has since faltered, dropping to a low of 119p at the turn of the year. The shares were trading at 142p on Friday. What does the company say? In a mid-July update Ideagen reported revenue up 29% to £46.7 million over the year to end April as it switched to a subscription basis, with contracts signings up 77% over the period, 87% of which were made outside the UK. Recurring revenue rose from 62% to 67%. What’s the outlook? Canaccord reiterated a buy last month as it lifted its target price from 170p to 180p, putting it just above a median City target of 177p. After briefly climbing to a premium multiple in 2018 the consolidation has restored a historic sector discount, at 23x forecast earnings versus 28x."
06/6/2019
22:36
rivaldo: Cannacord have raised their price target to 170p after the Capital Markets Day, and they see 80% upside on achievement of targets: Https://www.sharecast.com/news/broker-recommendations/canaccord-on-ideagen--5582378.html "Canaccord raises price target on 'confident' Ideagen Analysts at Canaccord Genuity raised their target price for British software firm Ideagen from 160p to 170p on Thursday, citing the group's "confident" growth outlook and an "attractive" valuation as their reasoning. Canaccord said Ideagen's capital markets day had highlighted the "attractiveness" of the risk and audit management software market, evidenced by high confidence in continued organic growth of more than 8% per annum with scope for acceleration to low-teens from 2020. The Canadian broker, which also reiterated its 'buy' rating on Ideagen, expects recurring revenues to surpass 70% in 2019, noting that they could even approach 80% by 2022, increasing the defensiveness of its shares. And the company's attractive earnings profile should be enriched by tuck-in M&A, where the firm's chief executive Ben Dorks and chairman David Hornsby had "a strong integration track record". "In the current uncertain macro times, the relative value of a reliable growth compounder such as Ideagen should go up, particularly as we see that most peers exhibiting similar growth and recurring revenue characteristics trade on 25+% higher multiples," said Canaccord. "We lift our target to 170p reflecting higher conviction in growth delivery, re-rated peers and rolling forward our DCF. Our target implies 20% upside but we highlight ~80% potential assuming management delivers on its '£100m revenues and £30m EBITDA' target for FY22."
28/4/2019
07:06
glasshalfull: I’m currently writing a brief synopsis on each of my holdings...& IDEA remains one of the cornerstones of it. Not sure if the earnings table can be transferred over so here’s the link HTTPS://twitter.com/glasshalfull1/status/1122073947959439362?s=12 SPRING PORTFOLIO 2019 WRITE-UPS (1) IDEA (IDEAGEN PLC) - Mr Dependable * Share Price 147p * M/Cap £323m * Enterprise Value £324m * Shares in Issue 219.8m * Stock Rank 41 (Quality 67 / Value 4) Similar to my previous updates, Ideagen is now a 14x bagger for me in my 9-years invested & unsurprisingly remains a cornerstone of my portfolio. They provide Integrate Risk Management (IRM) software & services to organisations operating in highly regulated industries. We are talking industry sectors across the globe from aviation and healthcare to banking & finance. It has a global presence & a customer base that includes many of the world’s blue-chip companies. Over 4,700 organisations use Ideagen's products including 7 of the top 10 UK accounting firms, ALL of the top aerospace & defence companies AND 75% of the world's leading pharmaceutical companies. Importantly they have a fantastic customer retention rate which has been circa. 95% for as long as I can remember. In terms of the numbers, they released positive H1 results in Jan 2019 & highlighted continued strong growth with recurring revs rising to 67% which provides increased visibility on earnings. SaaS revenues grew at +80% & now comprise 26% of overall revenues. This is a v important metric to watch as it de-risks forecasts & reliance of one-off software licence revenues. Ideagen has delivered 8 years of unbroken double-digit EPS growth. Worth pointing out that the growth in EPS is forecast at only +15% in FY19 simply due to a £20m placing in Sept 2018 (142p) & the subsequent timing of acquisitions. Yr end April Revenue Adj PBT Adj EPS 2010 £1.0m £0.2m 0.6p 2011 £2.3m £0.5m (+150%) 0.9p (+50%) 2012 £4.0m £1.0m (+100%) 1.26p (+40%) 2013 £6.5m £1.9m (+90%) 1.55p (+33%) 2014 £9.0m £2.6m (+37%) 1.7p (+12%) 2015 £14.4m £3.6m (+38%) 2.1p (+27%) 2016 £21.9m £5.7m (+58%) 2.7p (+26%) 2017 £27.1m £6.9m (+22%) 3.2p (+19%) 2018 £36.1m £9.7m (+40%) 4.2p (+32%) 2019e £46.5m £12.1m (+25%) 4.8p (+15%) I met the team early in 2019 at their H1 FY19 presentation & came away v impressed. In his first year as CEO, Ben Dorks has done an excellent job, with a superb grip on operational performance. This builds on the excellent development of the company under David Hornsby & I believe they are in very capable hands. By FY22 IDEA are targeting £100m revenue at 30% EBITDA margin with 74% of revenue recurring. finnCap have a 180p price target which is +22% from the current price. While this may appear a touch rich at a first glance, I’d suggest that it’s warranted as they’ve delivered in spades in the last 9-years; operate in a risk management market growing at +13% per annum; have fantastic client retention; strong recurring revenues & an offering that has increased enormously in breadth & depth via 16 x acquisitions that have delivered an enviable product set across multiple industries throughout the globe. Yes, Ideagen is my number 1, my GOALIE in the portfolio team & a company I believe my Mr DEPENDABLE. I’m sure it will remain a core holding for some time to come 😁 Kind regards, GHF
Ideagen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IDEA
Ideagen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201129 05:11:39